Syndax Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting
March 29, 2017 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update
March 02, 2017 16:05 ET
|
Syndax Pharmaceuticals, Inc.
Encore 601 refractory melanoma cohort to proceed to second stage of Phase 2; pre-specified objective response criteria satisfiedEnrollment of the first stage of both NSCLC cohorts completed; decision...
Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
February 27, 2017 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple...
Syndax to Announce Fourth Quarter and Year-end 2016 Financial Results and Host Conference Call and Webcast on March 2, 2017
February 16, 2017 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its fourth quarter 2016 financial results on Thursday, March 2, 2017, after the close of...
Syndax Appoints Richard P. Shea as Chief Financial Officer
February 09, 2017 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board
January 31, 2017 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors
January 05, 2017 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
Syndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer
December 14, 2016 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and...
Syndax Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference
November 21, 2016 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple...
Syndax Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
November 10, 2016 16:01 ET
|
Syndax Pharmaceuticals, Inc.
Execution on clinical timelines and advancement of oncology programs continues with initiation of: Phase 2 cohorts of ENCORE 601 in NSCLC and melanomaPhase 1 clinical trial of SNDX-6352 WALTHAM,...